Nectar Lifesciences Limited (BOM:532649)
India · Delayed Price · Currency is INR 13.49
+0.15 (1.12%)
At close: Feb 13, 2026
Nectar Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 16,700 | 16,700 | 16,841 | 15,237 | 16,688 | 15,433 |
Other Revenue | 3.92 | 3.92 | 4.84 | 0.25 | 0.25 | 0.25 |
Revenue | 16,704 | 16,704 | 16,846 | 15,237 | 16,689 | 15,433 |
Revenue Growth (YoY) | -0.66% | -0.84% | 10.56% | -8.70% | 8.13% | -34.78% |
Cost of Revenue | 13,885 | 13,885 | 12,195 | 11,593 | 12,231 | 11,571 |
Gross Profit | 2,819 | 2,819 | 4,650 | 3,644 | 4,457 | 3,862 |
Selling, General & Admin | 990.95 | 985.1 | 865.6 | 796.01 | 763.07 | 751.49 |
Other Operating Expenses | 2,109 | 2,095 | 2,249 | 2,309 | 2,109 | 1,888 |
Operating Expenses | 3,723 | 3,704 | 3,722 | 3,696 | 3,441 | 3,362 |
Operating Income | -904.27 | -884.66 | 928.4 | -51.72 | 1,016 | 499.91 |
Interest Expense | -1,073 | -770.54 | -896.23 | -827.98 | -699.44 | -857.65 |
Interest & Investment Income | 14.89 | 14.89 | 123.9 | 17.26 | 18.84 | 26.82 |
Currency Exchange Gain (Loss) | 385.27 | 385.27 | 97.5 | 98.78 | 4.68 | -84.92 |
Other Non Operating Income (Expenses) | -360.51 | -360.51 | -72.68 | -65.67 | -93.34 | -177.78 |
EBT Excluding Unusual Items | -1,937 | -1,616 | 180.89 | -829.33 | 246.71 | -593.62 |
Gain (Loss) on Sale of Investments | 0.35 | 0.35 | 1.8 | 1.05 | 0.03 | 0.4 |
Gain (Loss) on Sale of Assets | -0.14 | -0.14 | - | 404.08 | 94.07 | -1.31 |
Other Unusual Items | 881.51 | - | - | - | - | -253.15 |
Pretax Income | -1,056 | -1,615 | 182.69 | -424.2 | 340.81 | -847.68 |
Income Tax Expense | -591 | -478.53 | 132.74 | -182.37 | 90.34 | -115.04 |
Net Income | -3,551 | -1,137 | 49.95 | -241.83 | 250.47 | -732.64 |
Net Income to Common | -3,551 | -1,137 | 49.95 | -241.83 | 250.47 | -732.64 |
Shares Outstanding (Basic) | 224 | 224 | 224 | 224 | 224 | 224 |
Shares Outstanding (Diluted) | 224 | 224 | 224 | 224 | 224 | 224 |
EPS (Basic) | -15.86 | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 |
EPS (Diluted) | -15.86 | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 |
Free Cash Flow | - | 1,256 | 1,953 | 1,036 | 700.35 | -98.62 |
Free Cash Flow Per Share | - | 5.60 | 8.71 | 4.62 | 3.12 | -0.44 |
Gross Margin | 16.88% | 16.88% | 27.61% | 23.92% | 26.71% | 25.02% |
Operating Margin | -5.41% | -5.30% | 5.51% | -0.34% | 6.09% | 3.24% |
Profit Margin | -21.26% | -6.81% | 0.30% | -1.59% | 1.50% | -4.75% |
Free Cash Flow Margin | - | 7.52% | 11.59% | 6.80% | 4.20% | -0.64% |
EBITDA | -267.85 | -260.77 | 1,536 | 539.47 | 1,586 | 1,102 |
EBITDA Margin | -1.60% | -1.56% | 9.12% | 3.54% | 9.50% | 7.14% |
D&A For EBITDA | 636.42 | 623.89 | 607.18 | 591.19 | 569.68 | 602.53 |
EBIT | -904.27 | -884.66 | 928.4 | -51.72 | 1,016 | 499.91 |
EBIT Margin | -5.41% | -5.30% | 5.51% | -0.34% | 6.09% | 3.24% |
Effective Tax Rate | - | - | 72.66% | - | 26.51% | - |
Revenue as Reported | 16,750 | 16,750 | 16,987 | 15,668 | 16,802 | 15,471 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.